U.S. Markets open in 5 hrs 12 mins
  • S&P Futures

    4,196.00
    +1.75 (+0.04%)
     
  • Dow Futures

    34,446.00
    +4.00 (+0.01%)
     
  • Nasdaq Futures

    13,610.75
    +13.00 (+0.10%)
     
  • Russell 2000 Futures

    2,242.40
    +2.50 (+0.11%)
     
  • Crude Oil

    64.57
    -0.14 (-0.22%)
     
  • Gold

    1,820.70
    +5.00 (+0.28%)
     
  • Silver

    27.46
    -0.02 (-0.06%)
     
  • EUR/USD

    1.2083
    +0.0015 (+0.1208%)
     
  • 10-Yr Bond

    1.5610
    0.0000 (0.00%)
     
  • Vix

    18.47
    -0.68 (-3.55%)
     
  • GBP/USD

    1.3928
    +0.0036 (+0.2577%)
     
  • USD/JPY

    109.1340
    +0.0490 (+0.0449%)
     
  • BTC-USD

    55,650.34
    -1,299.12 (-2.28%)
     
  • CMC Crypto 200

    1,451.40
    -20.01 (-1.36%)
     
  • FTSE 100

    7,099.27
    +23.10 (+0.33%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

What Is The Ownership Structure Like For Destiny Pharma plc (LON:DEST)?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in Destiny Pharma plc (LON:DEST) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

With a market capitalization of UK£74m, Destiny Pharma is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Destiny Pharma.

Check out our latest analysis for Destiny Pharma

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Destiny Pharma?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Destiny Pharma does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Destiny Pharma, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Destiny Pharma. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Destiny Pharma's case, its Top Key Executive, William Love, is the largest shareholder, holding 11% of shares outstanding. With 7.9% and 5.2% of the shares outstanding respectively, Jemima Wade and Rosetta Capital Limited are the second and third largest shareholders.

We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Destiny Pharma

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

It seems insiders own a significant proportion of Destiny Pharma plc. It has a market capitalization of just UK£74m, and insiders have UK£23m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public holds a 30% stake in Destiny Pharma. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 5.2% stake in Destiny Pharma. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

It seems that Private Companies own 9.2%, of the Destiny Pharma stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Destiny Pharma better, we need to consider many other factors. Be aware that Destiny Pharma is showing 6 warning signs in our investment analysis , and 3 of those are significant...

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.